Stocks · BLISSGVS

Bliss GVS Pharma delivery percentage & share price.

· data for the trading session of Wed 18 Nov 2026

Last close · 18 Nov 2026
₹680.35 +3.66%
NSE: BLISSGVS · BSE: 506197
⚠ Under NSE surveillance: Long-term ASM Stage IV
Sector: Pharma & healthcare · RS rating 99
1W+3.7%1M+8.5%3M+18.6%6M+134.6%1Y+310.1%
52-week range
₹140.80-8.0% from the high₹739.90

Price, volume and delivery

Candles adjusted for splits and bonuses. In the lower panel, the grey bar is the day’s volume and the coloured bar is the part that was delivered; bright green marks big-buyer days (delivered shares 3× the stock’s normal or more, with a normal-or-higher delivery %).

Bliss GVS Pharma share price today: what happened on 18 November

Written from NSE’s end-of-day data for 18 Nov 2026. Updated every trading evening. Facts, not advice.

Bliss GVS Pharma rose to ₹680.35 on Wednesday, 18 November 2026, up ₹24.00 or 3.66% from the previous close of ₹656.35. It opened at ₹660.90 and traded between ₹652.00 and ₹688.90, a range of 5.6% of its price, and finished in the middle of it. Among the 126 Pharma & healthcare stocks we track, it ranked 7th by today’s move; the typical stock in the sector moved -0.53%.

It closed higher on 6 of the last 10 sessions and is +9.8% over that stretch. Looking further back: one week +3.7%, one month +8.5%, three months +18.6%, one year +310.1%. Its relative strength (RS) rating is 99 on a 1–99 scale, which means its 12-month performance beats about 99% of the 1,443 most traded NSE stocks.

2.58 lakh shares changed hands, worth about ₹17.4 crore, 1.4 times the 20-session average. Of those, 0% (0 shares) were taken for delivery, meaning they actually changed owners instead of being traded within the day. That compares with a 60-session average of 0%. There were no big-buyer days (delivery several times above normal) in the last three months.

The close is 2.2% above the 50-day average of ₹665.93 and 55.4% above the 200-day average of ₹437.81. The 14-day RSI, a 0–100 gauge of recent momentum, reads 57, in the neutral zone between 30 and 70. It sits 8.0% below its 52-week high of ₹739.90 and 383.2% above the low of ₹140.80, in the upper part of the year’s range.

Looking at where shares were actually delivered over the past year, the busiest price zone below today’s close is around ₹427 (-37.2%). Prices often slow down near such zones because many holders bought there, but they are history, not predictions.

NSE has it under surveillance (Long-term ASM Stage IV), which can mean tighter trading rules.

On a typical day Bliss GVS Pharma moves about ±3.6%, and its average session spans 5.0% from high to low. It closed higher on 55% of the sessions in the past year. It opened with a gap of 1% or more 79 times in that year (45 up, 34 down). Its best day of the year was 26 May 2026 (+20.00%) and its worst was 10 December 2025 (-7.52%).

Last five sessions

DayCloseChangeVolumeDelivery
Wed 18 Nov₹680.35+3.66%2.58 lakh0%
Tue 17 Nov₹656.35-0.52%63,1380%
Mon 16 Nov₹659.80-1.98%1.26 lakh0%
Fri 13 Nov₹673.10+4.92%4.09 lakh0%
Thu 12 Nov₹641.55-2.25%74,2140%

Price levels by delivered volume

Where the most Bliss GVS Pharma shares were actually delivered over the last year. Each day’s delivered shares are spread across that day’s high–low range; the peaks are the busiest price zones. Below the close: support zones; above: resistance zones. History, not a forecast.

₹680₹427₹276₹215
  • Last close₹680.3518 Nov
  • Support 1₹427-37.2% · 4.2% of the year’s delivery
  • Support 2₹276-59.4% · 9.9% of the year’s delivery
  • Support 3₹215-68.3% · 12.1% of the year’s delivery

Bliss GVS Pharma score

Ranked 0–100 against 1,356 NSE stocks (prices of 18 Nov 2026). Relative ranks for learning, not advice.

Quality
73 /100
Strong
#27 of 116 in Pharma & healthcare
Valuation
44 /100
Fair
#63 of 111 in Pharma & healthcare
Momentum
90 /100
Strong
#10 of 114 in Pharma & healthcare

Passes 10 of 15 checks on the 18-point checklist.

See how Bliss GVS Pharma’s scores are made and the full checklist →

Bliss GVS Pharma at a glance

  • Bliss GVS Pharma closed at ₹680.35 on 18 Nov 2026 (+3.66% on the day). Over the past year it is +310.07%, against -2.39% for NIFTY 50.
  • It trades 8.0% below its 52-week high of ₹739.90 and 383.2% above its low of ₹140.80.
  • 0% of the shares traded on 18 Nov were delivered, against a 60-session average of 0%.
  • There were no big-buyer days (delivery far above normal) in the last three months.
  • A typical day moves it about ±3.6%: more volatile than 92% of the 1,443 most traded NSE stocks.
  • Fundamentals: P/E 44.7 · Profit +92% YoY.

Bliss GVS Pharma company details

From the exchanges’ own records: NSE and BSE listings and their industry classification.

Sector
Pharma & healthcare
Industry
Pharmaceuticals
Macro sector
Healthcare
ISIN
INE416D01022
NSE symbol
BLISSGVS
BSE code
506197
Listed on NSE since
26 July 2010
Face value
₹1 per share

Bliss GVS Pharma pros and cons

Written automatically from the latest results, shareholding, valuation against its sector, and price and delivery data. Facts, not advice.

Pros

  • Almost debt-free: borrowings are under 10% of equity.
  • Profit has grown for 3 quarters in a row.
  • Profit up 92% on a year ago (quarter ended Sep 2026).
  • Sales up 28% on a year ago.
  • Promoters raised their holding by 15.06 points, to 50.1%.
  • Relative strength rating 99 out of 99: it has outperformed most stocks over the past year.

Cons

  • Foreign investors (FIIs) cut their stake by 3.0 points last quarter, to 5.0%.
  • More volatile than 92% of the most traded NSE stocks.

Bliss GVS Pharma stock DNA

Where Bliss GVS Pharma sits among the 1,443 most traded NSE stocks, on a 0–100 scale: 0 is the lowest of all of them, 100 the highest. From the last year of daily data. The first row is the RS rating used on our relative strength ranking.

Relative strength (RS rating)12-month return, latest quarter counted twice
Weak
Strong
99/100
Volatility58% a year
Calm
Wild
92/100
Daily range5.0% high to low
Tight
Wide
85/100
Opening gaps32% of days gap 1%+
Rare
Often
86/100
Delivery0% of volume delivered
Traders
Holders
0/100
Liquidity₹12.4 Cr a day
Thin
Deep
53/100
1-year return+310.1%
Laggard
Leader
100/100
Gap-ups of 1%+ (1 year)4562% filled the same day
Gap-downs of 1%+3471% filled the same day
Up days55%of the last 250 sessions
Streak1 upsessions in a row

How Bliss GVS Pharma usually moves

Every session of the last year by size of move. The white line is the last session.

-8.0% to -7.0%: 2 days-7.0% to -6.0%: 3 days-6.0% to -5.0%: 3 days-5.0% to -4.0%: 12 days-4.0% to -3.0%: 15 days-3.0% to -2.0%: 18 days-2.0% to -1.0%: 32 days-1.0% to +0.0%: 27 days+0.0% to +1.0%: 37 days+1.0% to +2.0%: 27 days+2.0% to +3.0%: 22 days+3.0% to +4.0%: 9 days+4.0% to +5.0%: 23 days+5.0% to +6.0%: 3 days+6.0% to +7.0%: 5 days+7.0% to +8.0%: 4 days+8.0% to +9.0%: 2 days+9.0% to +10.0%: 6 days-10%-8%-6%-4%-2%+0%+2%+4%+6%+8%+10%Dashed lines: a normal day, ±3.6%Last session +3.66%

Best day 26 May 2026 (+20.00%), worst 10 Dec 2025 (-7.52%).

Bliss GVS Pharma vs NIFTY 50, one year

Both start at 100. The shaded gap is how far Bliss GVS Pharma is ahead of or behind the market.

100Dec 25Mar 26Jun 26Sep 26Bliss GVS Phar +304.0%NIFTY 50 -2.8%

Bliss GVS Pharma fundamentals

Quarterly results and shareholding from NSE filings. Profit is the share owed to the company’s own shareholders. Compare in the stock screener →

Market cap₹7,232 Crshares × last price
P/E (TTM)44.7on ₹15.22 EPS, last 4 quarters
Revenue₹313 CrQ2 FY27 · +28.22% YoY
Net profit₹52 CrQ2 FY27 · +91.74% YoY

Revenue

₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.

Q4 FY25: ₹198 Cr198Q4 FY25Q1 FY26: ₹207 Cr207Q1 FY26Q2 FY26: ₹244 Cr244Q2 FY26Q3 FY26: ₹218 Cr218Q3 FY26Q4 FY26: ₹257 Cr257Q4 FY26Q1 FY27: ₹286 Cr286Q1 FY27Q2 FY27: ₹313 Cr313Q2 FY27

Net profit

₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.

Q4 FY25: ₹16 Cr16Q4 FY25Q1 FY26: ₹43 Cr43Q1 FY26Q2 FY26: ₹27 Cr27Q2 FY26Q3 FY26: ₹23 Cr23Q3 FY26Q4 FY26: ₹36 Cr36Q4 FY26Q1 FY27: ₹50 Cr50Q1 FY27Q2 FY27: ₹52 Cr52Q2 FY27

Who owns Bliss GVS Pharma

Shareholding pattern for the quarter to 30 Sep 2026, from the company’s filing with NSE.

Promoters 50.1%Foreign investors (FII/FPI) 5.0%Insurance companies 1.5%Other domestic institutions 8.1%Retail investors 23.0%Others 12.3%

Change since Jun 2026:

Promoters+15.06 ptsForeign investors-3.04 ptsMutual funds-0.26 ptsInsurance companies-1.71 ptsOther domestic institutions+2.12 ptsRetail investors-6.79 pts

Promoter holding over time

Promoter and promoter group stake, every quarter.

2021-092026-0933.19%50.07%

Bliss GVS Pharma balance sheet, returns and cash flow

From the consolidated half-year and annual results filed with NSE (latest: 30 Sep 2026), on the same basis as the quarterly figures above.

ROE13.3%profit ÷ shareholders’ equity, last 4 quarters
ROCE19.8%operating profit ÷ capital employed
Debt / equity0.00borrowings (excl. leases) ÷ equity
Book value / share₹121.39P/B 5.6
Interest cover33.0×operating profit ÷ interest
Free cash flow FY26₹81.9 Cryield 1.1% of market cap
EV / EBITDA25.2×enterprise value (market cap + debt − cash) ÷ operating profit before interest, tax and depreciation, last 4 quarters
Dividend payout FY268%share of the year’s profit paid out as dividends
Net margin trend+5.5 ptsnet margin 16.7% in Q2 FY27 vs 11.1% a year earlier
Sep 2025half yearMar 2026full yearSep 2026half year
Shareholders’ equity₹1,132 Cr₹1,193 Cr₹1,290 Cr
Borrowings (excl. leases)₹36.0 Cr₹2.9 Cr₹0.0 Cr
Cash, bank balances & current investments₹201 Cr₹168 Cr₹151 Cr
Operating cash flow₹77.5 Cr₹139 Cr₹35.7 Cr
Capex (PPE + intangibles)₹29.2 Cr₹56.8 Cr₹31.7 Cr

Balance sheet items are as at the date shown; cash flows cover the half year or full year to that date. ₹ crore.

Bliss GVS Pharma vs peers

Bliss GVS Pharma is number 70 of 121 Pharma & healthcare companies by market cap. The table shows it with the 7 companies nearest to it in size. P/E is on the last four quarters’ profit, growth compares the latest quarter with a year earlier, Q / V / M are ChartMine scores (quality, valuation, momentum, 0–100) for 17 Nov 2026. Tap a column heading to sort.

Thyrocare Technologies503.608,01656.014.526.225%−68%6%−5%893753
Suven Life Sciences265.657,507–16.6−104.030%––49%24–50
Sanofi India3,2327,43320.49.044.13%54%24%−29%816343
Bliss GVS Pharma680.357,23244.75.613.328%92%17%310%734784
NEPHROPLUS653.006,56650.35.510.8––11%–524567
SPARC190.126,1693.84.3113.4282%–−81%46%785664
FDC373.906,08719.42.312.321%73%9%−9%586961
Innova Captab1,0506,01036.05.115.230%43%9%43%585061
Sector median–9,49542.04.513.321%26%12%12%544764

Sector: Pharma & healthcare (126 companies). Medians are over every Pharma & healthcare company with that figure. ₹ crore; market cap at the last close.

Bliss GVS Pharma cash flow

Cash generated by the business, spent on investment and returned to or raised from investors, by fiscal year (consolidated figures from the annual results). Operating cash flow covered profit in 2 of the last 2 years. Free cash flow was positive in 2 of 2 years.

YearOperating cash flowInvestingFinancingCapexFree cash flowProfitCash conversionDividends paid
FY26139−38−895782135103%11
FY25106−75−30763090117%5

₹ crore. Free cash flow = operating cash flow − capex. Cash conversion = operating cash flow ÷ profit. Capex and dividends are cash paid out.

Operating cash flow vs profit

₹ crore by fiscal year. When the blue bar is taller than the green one, the business turned more than its reported profit into cash.

Operating cash flowProfitFY25 Operating cash flow: ₹106 Cr106FY25 Profit: ₹90 Cr90FY25FY26 Operating cash flow: ₹139 Cr139FY26 Profit: ₹135 Cr135FY26

Bliss GVS Pharma dividend history, bonus and splits

From NSE’s corporate-action records since 2005. Prices on this page are already adjusted for splits and bonuses.

Bliss GVS Pharma dividend history

Total declared per share in each year, as announced (not adjusted for later splits or bonuses). Last 12 months: ₹1.5 a share, a 0.22% yield at today’s price.

YearDividend per sharePayouts
2026₹1.52
2025₹0.51
2024₹0.51
2023₹0.51
2022₹0.51
2021₹0.51
2020₹0.51
2019₹11
2018₹11
2017₹0.61
2016₹0.51
2015₹0.72

Latest: Dividend ₹1 (ex 8 Jul 2026); Interim ₹0.5 (ex 18 Feb 2026); Dividend ₹0.5 (ex 24 Jul 2025); Dividend ₹0.5 (ex 18 Jul 2024).

Delivery and big-buyer days

Delivered shares change owners for real; intraday trades don’t. Days when delivery jumps far above normal often mean large investors were buying or selling.

Delivery, last session0%0 shares
Average, 60 sessions0%1-year median 25%
Big-buyer days, 1 year10delivery 3× normal or more

Delivery calendar, last 12 months

Each square is a session. The brighter the green, the more shares were delivered compared with Bliss GVS Pharma’s normal. Hover or tap a square for the day.

MWFDecJanFebMarAprMayJunJulAugSepOctNov
Hover a square
QuietBelow normalNormalHighBig-buyer day

Latest big-buyer days

What the price did on the day and five sessions later. Past moves only.

DateDeliveredvs normalDelivery %Day5 days later
25 May 202633.57 L5.8×34%+5.73%+36.81%
14 May 202619.34 L3.7×44%+3.52%+2.00%
13 Feb 202616.70 L3.8×25%-0.17%+2.50%
12 Feb 202618.41 L4.2×30%+1.86%+3.79%
11 Feb 202624.52 L5.6×26%+2.96%+7.37%
10 Feb 202622.81 L5.3×23%+2.20%+11.12%
9 Feb 202624.59 L5.7×27%+11.14%+9.02%
29 Jan 202617.88 L5.0×25%+9.18%+0.63%

Bliss GVS Pharma timeline

Everything that happened to Bliss GVS Pharma, newest first: deals, promoter filings, results, big-buyer days, new highs and big moves.

  • October 2026
  • 27 Oct
    Large holder Catalyst Trusteeship Limited Acting As Debenture Trustee On Behalf Of Debenture Holders bought 5.10 Cr shares47.95% of the company (off market / other); holds 47.95% after. Filed with NSE.
  • 8 Oct
    Promoter Anupam Rasayan India Ltd bought 5.10 Cr shares47.95% of the company (off market / other); holds 51.61% after. Filed with NSE.
  • August 2026
  • 19 Aug
    New 52-week high at ₹573.80First new high in 36 sessions.
  • July 2026
  • 8 Jul
    Dividend - Re 1 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
  • May 2026
  • 26 May
    Jumped 20.0% in one sessionClosed at ₹381.05, about 5.5× a normal day’s move.
  • 25 May
    Big-buyer day: 33.57 L shares delivered, 5.8× normal34% of the day’s volume was delivered; the price closed +5.73%.
  • 14 May
    Big-buyer day: 19.34 L shares delivered, 3.7× normal44% of the day’s volume was delivered; the price closed +3.52%.
  • April 2026
  • 7 Apr
    New 52-week high at ₹245.00First new high in 31 sessions.
  • February 2026
  • 18 Feb
    Interim Dividend - Re 0.50 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
  • 13 Feb
    Big-buyer day: 16.70 L shares delivered, 3.8× normal25% of the day’s volume was delivered; the price closed -0.17%.
  • 12 Feb
    Big-buyer day: 18.41 L shares delivered, 4.2× normal30% of the day’s volume was delivered; the price closed +1.86%.
  • 11 Feb
    Big-buyer day: 24.52 L shares delivered, 5.6× normal26% of the day’s volume was delivered; the price closed +2.96%.
  • 10 Feb
    Big-buyer day: 22.81 L shares delivered, 5.3× normal23% of the day’s volume was delivered; the price closed +2.20%.
  • 9 Feb
    Big-buyer day: 24.59 L shares delivered, 5.7× normal27% of the day’s volume was delivered; the price closed +11.14%.
  • 9 Feb
    New 52-week high at ₹205.80First new high in 22 sessions.
  • 9 Feb
    Jumped 11.1% in one sessionClosed at ₹203.60, about 3.1× a normal day’s move.
  • January 2026
  • 29 Jan
    Big-buyer day: 17.88 L shares delivered, 5.0× normal25% of the day’s volume was delivered; the price closed +9.18%.
  • 6 Jan
    New 52-week high at ₹192.00First new high in over 20 sessions.
  • 6 Jan
    Jumped 13.8% in one sessionClosed at ₹182.48, about 3.8× a normal day’s move.
  • December 2025
  • 10 Dec
    Big-buyer day: 7.40 L shares delivered, 5.2× normal34% of the day’s volume was delivered; the price closed -7.52%.
  • 1 Dec
    Big-buyer day: 4.48 L shares delivered, 3.5× normal48% of the day’s volume was delivered; the price closed -6.15%.
  • August 2025
  • 20 Aug
    Big-buyer day: 13.38 L shares delivered, 7.8× normal27% of the day’s volume was delivered; the price closed -4.41%.
  • July 2025
  • 24 Jul
    Annual General Meeting/Dividend - Rs 0.50 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
  • June 2025
  • 27 Jun
    Big-buyer day: 6.05 L shares delivered, 3.8× normal41% of the day’s volume was delivered; the price closed +5.96%.

My notes on Bliss GVS Pharma

Private: saved only in this browser, never sent to us.

Questions

What is the 52-week high and low of Bliss GVS Pharma?
Over the last 52 weeks, Bliss GVS Pharma (BLISSGVS) traded between ₹140.80 and ₹739.90 (adjusted for splits and bonuses). The last close of ₹680.35 on 18 Nov 2026 is 8.0% below the high.
What is the delivery percentage of Bliss GVS Pharma?
On 18 Nov 2026, 0.0% of Bliss GVS Pharma’s traded shares were delivered. The 60-session average is 0.0%, and its median over the last year is 25.1%.
How volatile is Bliss GVS Pharma?
Bliss GVS Pharma’s daily moves over the last year add up to 58% annual volatility, higher than 92% of the 1,443 most traded NSE stocks. Its average day spans 5.0% from high to low.
What is the market cap of Bliss GVS Pharma?
About ₹7,232 Cr, from 106,300,000 shares at the last close.
What is the P/E ratio of Bliss GVS Pharma?
44.7, the last close divided by earnings per share of ₹15.22 over the last four reported quarters.
Who owns Bliss GVS Pharma? What is its shareholding pattern?
As of 30 Sep 2026: promoters 50.07%, foreign investors 5.03%, mutual funds 0.00%, insurance companies 1.53% and retail investors 22.98%.
How were Bliss GVS Pharma's latest quarterly results?
In Q2 FY27 (quarter to 30 Sep 2026), revenue was ₹313 Cr (+28.22% year on year) and net profit ₹52 Cr (+91.74%).
What is the ROE of Bliss GVS Pharma?
Bliss GVS Pharma’s return on equity was 13.3% over the last four quarters: profit attributable to shareholders divided by average shareholders’ equity (consolidated figures, balance sheet as at 30 Sep 2026).
Is Bliss GVS Pharma debt free?
Almost: borrowings (excluding lease liabilities) were 0.00× equity as at 30 Sep 2026.
What is the book value of Bliss GVS Pharma?
₹121.39 per share (consolidated shareholders’ equity as at 30 Sep 2026 divided by shares outstanding), a price-to-book of 5.6.
Who are Bliss GVS Pharma’s peers?
Among Pharma & healthcare companies listed on NSE, the ones closest to Bliss GVS Pharma by market cap are Thyrocare Technologies, Suven Life Sciences, Sanofi India, NEPHROPLUS, SPARC, FDC and Innova Captab. Pharma & healthcare has 126 companies in ChartMine’s data. Bliss GVS Pharma has a P/E of 44.7 against the sector median of 42.0 and a return on equity of 13.3% against 13.3%.
Does Bliss GVS Pharma generate cash?
In FY26, Bliss GVS Pharma’s operating cash flow was ₹139 crore against profit of ₹135 crore (103% cash conversion); after ₹57 crore of capex, free cash flow was ₹82 crore. Operating cash flow covered profit in 2 of the last 2 years, and free cash flow was positive in 2 of 2.
Has Bliss GVS Pharma given bonus shares or split its stock?
NSE’s corporate-action records since 2005 show no bonus issue or stock split for Bliss GVS Pharma.
Does Bliss GVS Pharma pay dividends?
Yes. Bliss GVS Pharma’s most recent dividend was ₹1 a share (dividend, ex-date 8 Jul 2026). Over the last 12 months it declared ₹1.5 a share, a 0.22% yield at the latest price.
What are the support and resistance levels of Bliss GVS Pharma?
Over the last year, the most Bliss GVS Pharma shares were delivered around ₹427 below the current price (last close ₹680.35 on 18 Nov 2026). These busy zones often act as support and resistance, but they describe the past, not the future.
What is the ISIN of Bliss GVS Pharma?
Bliss GVS Pharma’s ISIN is INE416D01022. It trades on NSE as BLISSGVS and on BSE under code 506197, with a face value of ₹1 per share, and has been listed on NSE since 26 July 2010.

Data from NSE’s daily files, adjusted for splits and bonuses. Past behaviour is not a forecast. This is information, not investment advice; ChartMine is not a SEBI-registered adviser.

See it live on your chart.ChartMine for TradingView.